Analysts Set Solventum Corporation (NYSE:SOLV) Price Target at $87.00

Shares of Solventum Corporation (NYSE:SOLV) have been assigned an average recommendation of “Hold” from the thirteen brokerages that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $87.00.

A number of research firms recently commented on SOLV. Wells Fargo & Company lifted their price objective on Solventum from $79.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Monday, September 15th. UBS Group restated a “neutral” rating on shares of Solventum in a report on Friday, November 21st. Zacks Research downgraded shares of Solventum from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 1st. Jefferies Financial Group began coverage on shares of Solventum in a research note on Thursday, September 11th. They issued a “hold” rating and a $80.00 price objective on the stock. Finally, Piper Sandler reissued an “overweight” rating on shares of Solventum in a research note on Wednesday, December 17th.

Institutional Investors Weigh In On Solventum

Several institutional investors and hedge funds have recently made changes to their positions in SOLV. Allworth Financial LP grew its stake in Solventum by 2.8% during the third quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock worth $350,000 after purchasing an additional 129 shares during the period. CIBC Private Wealth Group LLC grew its position in shares of Solventum by 0.5% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock worth $1,804,000 after buying an additional 134 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in shares of Solventum by 0.7% in the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,778 shares of the company’s stock valued at $1,500,000 after acquiring an additional 140 shares in the last quarter. BOKF NA lifted its position in shares of Solventum by 6.9% during the 3rd quarter. BOKF NA now owns 2,193 shares of the company’s stock valued at $160,000 after acquiring an additional 141 shares during the period. Finally, CHICAGO TRUST Co NA boosted its stake in Solventum by 3.0% during the third quarter. CHICAGO TRUST Co NA now owns 5,188 shares of the company’s stock worth $379,000 after acquiring an additional 150 shares in the last quarter.

Solventum Stock Performance

NYSE SOLV opened at $80.45 on Friday. The company has a market capitalization of $13.95 billion, a price-to-earnings ratio of 9.27, a PEG ratio of 8.49 and a beta of 0.25. The company has a quick ratio of 1.14, a current ratio of 1.50 and a debt-to-equity ratio of 1.03. Solventum has a twelve month low of $60.70 and a twelve month high of $88.20. The stock has a fifty day simple moving average of $77.73 and a 200 day simple moving average of $74.87.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Thursday, November 6th. The company reported $1.50 EPS for the quarter, beating analysts’ consensus estimates of $1.43 by $0.07. The firm had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.05 billion. Solventum had a return on equity of 28.01% and a net margin of 18.13%.The business’s revenue was up .7% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.64 EPS. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. Sell-side analysts expect that Solventum will post 6.58 EPS for the current year.

Solventum announced that its Board of Directors has approved a share buyback plan on Thursday, November 20th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the company to buy up to 7.5% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its stock is undervalued.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.